Clinical Experience, Pathophysiology, and Considerations in the Prophylaxis and Treatment of Hypercoagulopathy of COVID-19: A Review Study

摘要: Since the emergence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic, an increasing number reports and studies have tried to warn medical community about thrombotic complications coronavirus disease 2019 (COVID-19). It is suggested that hyperinflammatory response endothelial injury, especially in patients with disease, lead a hypercoagulable state. Sudden deaths occurring some also point fulminant arrhythmias massive pulmonary embolism (PE). Several expert panels published recommendations regarding prophylaxis treatment such complications. Nonetheless, there are limited high-quality for evidence-based decision-making, most these arisen from descriptive studies, optimal anticoagulant agents dosages yet be designated. The coagulopathy persists after phase illness, recommend continuation deep vein thrombosis several days regaining normal daily activities by patient. Here, we review incidence possible mechanisms complications, present summary considerations adult population.